Featured Speaker: Jeffrey S. Kasher, PhD, Vice President and Chief Operating Officer, Global Clinical Development, ELI LILLY
About the session: As the biopharmaceutical industry is facing increasing healthcare reform and escalating market demands leading to major internal restructuring within their clinical research areas, sponsors are now more than ever, in search of a more efficient clinical research model where sourcing is a strategic component. A tactical, noncollaborative, single-trial large vendor pool approach will no longer work. Sponsors must take a logical, cross-functional approach in collecting and analyzing portfolio needs, critical trial criteria and vendor capability data leading to the development of a sourcing strategy which includes a select vendor pool that will ensure overall optimal value. During this session, you hear the lessons learned from Eli Lilly’s use of the functional outsourcing model in Latin America.
- • Review strategies and tactics for managing partnerships between pharmaceutical companies and CROs
- • Learn how to better leverage external expertise and improve the clinical trial process at your organization
- • Determine the amount of flexibility required by both the CRO and the sponsor to build an effective partnership
Saint-Guibert. Upon his return to Indianapolis in 2003, he served as operations director and then executive director for discovery biology in Lilly Research Labs, leading the transformation of the division into therapeutically-focused drug hunting teams. Most recently, Dr. Kasher served as the executive director of the osteoarthritis/rheumatoid arthritis platform team, leading the development of an integrated strategy for a portfolio of novel drug candidates.